US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech
The FDA has lifted its clinical hold on Bharat Biotech's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States

Hyderabad: Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States."Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the company's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States.
Ocugen, Inc is co-developing Bharat Biotech's Covaxin vaccine candidate for COVID-19 in USA and Canada," reads Bharat Biotech's statement.Earlier the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of 31 January, 2022.Read all the Latest News, Trending News, Cricket News, Bollywood News,India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Stroke is rising among young adults. Doctor explains why it's happening and what you must do
Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge
Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs
Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key
Organ donation: 5 myths you need to stop believing, according to a transplant specialist
